Guest guest Posted September 29, 2011 Report Share Posted September 29, 2011 September 30, 2011 HCV » October Newsletter » HCV Fact Sheets » Educational Materials » HCSP Streaming Videos Hello: This end of the month eblast is chock full of exciting news. HCV Advocate Newsletter-October 2011: In This Issue: Pharmasset: 98% to 100% Cure RatesAlan Franciscus, Editor-in-ChiefHealthWise: Reducing the Cost of Hepatitis C TreatmentLucinda K. Porter, RNDisability & Benefits: Medicare Enrollment ExplainedJacques Chamber, CLUHCV Snapshots Lucinda K. Porter, RNClinical TrialsAlan Franciscus, Editor-in-ChiefThe QUANTUM clinical study is a phase II interferon free study that will evaluate the safety and efficacy of Pharmasset's polymerase (nucleotide) inhibitors-PSI-7977, PSI-938 and ribavirin. Hepatitis C Treatments in Current Clinical Development: Updated September 26. Click here Just to let you know that we have added a new feature to the Drug Pipeline: Interferon Free Trials New Treatment Guidelines for Genotype 1 An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases Updated Factsheets:Similarities and Differences between HIV and HCVHepatitis C and LatinosSide Effect Management: Rashes Understanding HCV: A Patient Pocket Guide: Updated September 2011 To Download this Guide Click here HBV Journal Review: Updated September 30. Click here In This Issue: Young, Hepatitis B Patients Who Smoke Are at Higher Risk of Liver Cancer Treatment and Monitoring Recommendations for Asian-Americans Published High Doses of Lamivudine Effective in Patients with HBV-Related Cirrhosis New Tests Effective in Identifying Liver Inflammation Entecavir Ineffective in Patients with Lamivudine and Adefovir Resistance Patients with Core Antibody-But No Surface Antigen or Antibodies-May Have Hidden Infections and more.......... New: Flash Tattoo Fact Sheet: To Download this Fact Sheet Click here HBV and HCV Blog: Read about the latest and greatest in the news Consider Hepatitis C Infection in Some Arthritis Patinets Opinion: California needs a logical, uniform needle-exchange program Agenix submits manufacturing patent application for hepatitis B drug AGX-1009 Updated Hepatitis C Practice Guidelines Now Availalable from AASLD High-Risk Donor Livers Used with Greater Frequency in Transplantations Liver Cancer Incidence Lower in Nonalcoholic Fatty Liver Disease Patients than in those with Hepatitis C Living Donor Liver Transplantation Improves Survival Over Deceased Donor Transplants Respectfully, Alan Join us on Twitter - Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate www.hcvadvocate.org Editor-in-Chief, HBV Advocate www.hbvadvocate.org *Questions and Comments: If you have questions or comments please do not reply to this email. Questions and/or comments can be directed to alanfranciscus@... HBV » HBV Journal Review » HBV Factsheets » HBV & HCV Advocate Hepatitis Blog » Stay connected with all the late-breaking news on hepatitis B-Join us on Twitter Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.